Advising on investor participation in early and later stage funding rounds.
Advising early stage companies on UK set up issues such as grant funding, employment, tax structuring and real estate.
Advising a biotech company on heads of agreement for strategic collaborations with pharma companies on a biomarker platform for the diagnosis of diseases associated with aberrant gene expression and new sports drink.
Advising Shire Pharmaceuticals Group on employment aspects of its $200 million disposal of a pan-European pharmaceuticals business.
Patent and contractual due diligence exercises for a UK mid-sized pharma company relating to its proposed acquisitions and licensing-in of medicines.
Advising a biotech company on the research exemptions to patent infringement and their application to the use of RNAi libraries for elucidating the modes of action of new drugs.
Advising a generic pharmaceutical company on the validity of a patent protecting a blockbuster drug and on a litigation strategy in the English courts.
Acting for TDL Genetics in defence of a patent infringement action concerning a non-invasive pre-natal genetic test for foetal aneuploidies such as Down’s syndrome.
Acting in a highly complex international commercial arbitration against a multinational medical devices, pharmaceutical and consumer packaged goods manufacturer.
Defending Cardinal Health in an arbitration under the CIETAC rules in Beijing in relation to a claim for breach of confidentiality arising from an alleged misuse of technology.
Representing a diet clinic in UK copyright and trade mark infringement and passing off proceedings relating to a weight loss therapy and food and treatment plans.
Representing insurer for a private hospital group in claims by patients given breast implants filled with non-medical-grade silicone.